Rocket Pharmaceuticals (RCKT) Assets Average (2015 - 2026)

Rocket Pharmaceuticals has disclosed Assets Average across 12 years of filings, most recently posting $307.9 million for Q1 2026.

• Assets Average for Q1 2026 came in at $307.9 million, down 38.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $307.9 million (down 38.34% YoY), and the FY2025 annual result was $429.1 million, down 21.56% from the prior year.
• Assets Average came in at $307.9 million for Q1 2026 at Rocket Pharmaceuticals, down from $349.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $582.6 million in Q4 2023 to a low of $307.9 million in Q1 2026.
• The 5-year median for Assets Average is $472.9 million (2024), against an average of $461.9 million.
• Across the five-year window, Assets Average climbed 24.9% in 2023 and tumbled 38.34% in 2026, its largest moves.
• Rocket Pharmaceuticals' Assets Average stood at $484.5 million in 2022, then gained by 20.23% to $582.6 million in 2023, then fell by 20.92% to $460.7 million in 2024, then decreased by 24.19% to $349.2 million in 2025, then decreased by 11.83% to $307.9 million in 2026.
• The last three Assets Average figures came in at $307.9 million (Q1 2026), $349.2 million (Q4 2025), and $394.5 million (Q3 2025), per Business Quant data.